Molecular UTI Tests Find More Bacteria. Whether That Helps Patients Is Still Open

The most useful recent answer on molecular urine testing comes from a systematic review whose title concedes the point: results remain unclear [1]. Its authors searched PubMed, OVID and Embase for adult studies published between January 2023 and October 2025 and found 12 full-text articles. Two were randomised controlled trials, together enrolling 773 patients, mostly female and over 65. Against standard urine culture, PCR-based testing was more sensitive. It was not specific. In both trials, using the results to guide antibiotics reduced UTI symptoms over 28 days.

So there is a signal. It rests on two trials, in one age group, with a four-week endpoint, and a funding pattern that should give any reader pause: both randomised trials and five of the ten prospective studies were paid for by the companies that developed the tests [1].

The review is methodologically serious. It updates earlier scoping reviews, follows Cochrane and PRISMA standards, and is registered in advance (PROSPERO CRD420251070022) [1]. Of the 12 papers, seven appeared in clinical journals and five in microbiology journals. That split is worth noticing. Half the recent literature is about whether a test detects a sequence, and half is about whether a patient does better.

Why more sensitive and less specific are the same finding

A standard urine culture asks whether living bacteria will grow out of a urine sample. It is slow, a day or two, and it only sees organisms that tolerate the growth conditions it is given. A PCR test asks a different question. It amplifies a targeted stretch of DNA, and it does not require that the organism still be alive.

That distinction is not academic. A study of antibiotic effects on biofilms in Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae used quantitative PCR to measure genome-equivalent DNA inside biofilms, and its methods state the reason plainly: qPCR detects DNA from viable, dead, damaged or lysed cells, as well as extracellular DNA [6]. Dead bacteria leave DNA behind. A positive molecular result is evidence that a sequence was present, not proof of an active infection.

This is what "superior sensitivity despite lack of specificity" means in practice [1]. The test finds more. Some of what it finds is not causing disease. More positives means more prescriptions, and the review's clinical outcome data are too thin to show whether that trade is worth making.

A second problem is about definitions rather than technology. Even if a test detects E. coli, calling that isolate uropathogenic depends on a rule, and the rules do not travel. Researchers working in semi-rural Ecuador compared 124 virulence factor genes in ESBL-producing uropathogenic E. coli from clinical urine samples (n = 137) with E. coli selected for cephalosporin resistance from stool samples of healthy children nearby (n = 176) [9]. The best locally derived rule, the presence of at least one of upaH, cnf1 or sat, reached 56.2% sensitivity and 94.3% specificity. Published nonlocal definitions performed worse, with Youden's index between 0 and 0.361. Note the sensitivity figure: even the best local rule missed roughly 44% of the clinical isolates. And this was a study of bacterial isolates, not of patients being tested and then treated. It shows that "this is a pathogen" is a locally calibrated judgement, not a fixed property of a gene.

What the trials actually measured

The two randomised trials are the strongest part of the evidence, and they are modest. Their combined 773 patients were mostly female and over 65, so whatever the results mean, they mean that for that group. The only clinical outcome the review attributes to the trials is symptom reduction at 28 days; it describes the clinical outcome data overall as limited [1]. No longer-term outcomes are reported.

The review also cannot separate the test from the treatment decision built around it. In both trials the molecular result guided antibiotic therapy [1]. If symptoms improved, it is not obvious whether the gain came from better detection, from more antibiotics being given, or from both.

The stakes are documented elsewhere, though not in this review. A modelling analysis in Nature Communications estimates 1.03 million associated deaths (95% uncertainty interval 0.90 to 1.17 million) and 0.22 million attributable deaths (0.17 to 0.27 million) from carbapenem-resistant Gram-negative infections in 2021 [2]. That is a secondary analysis of modelled counterfactuals, not a tally of verified deaths, and it does not address urine testing. It explains why faster, better diagnosis is worth pursuing. It does not show that molecular urine tests deliver it.

Resistance adds another layer a detection test does not resolve. In a cross-sectional study of 60 Proteus isolates at a hospital in Lahore, 11.7% produced AmpC beta-lactamase by disc test, and resistance to amoxicillin-clavulanate was 93.3% [7]. That is one centre, one genus, one time window. Its relevance here is narrow: knowing that bacteria are present is a different question from knowing which drug will work, and the second question has local answers.

Where the evidence runs out

The honest summary is that the clinical case for molecular UTI testing is unproven, not disproven. Twelve papers, two of them randomised trials, is a thin base for a change in practice. The population studied was adults, and the review excluded studies involving only men or children, so nothing here speaks to paediatric or male-only UTI management [1].

The funding pattern limits what can be concluded about effect size. When both randomised trials and half the prospective studies are sponsored by the manufacturers of the tests being evaluated, independent replication is the obvious missing piece [1].

Several questions stay open. Does a more sensitive test reduce complications, or does it mostly add antibiotic courses? Does the benefit, if there is one, persist past four weeks? Does it hold in men, in children, or in people with catheters and recurrent infections? None of that is answered here.

The review's authors reach the same place. They call for prospective, multicentric studies to establish the role of these tests in UTI management [1]. Until those exist, a positive molecular result is one piece of evidence among several, and the decision to prescribe should still rest on symptoms, history and local resistance patterns rather than on the test's sensitivity alone.